BC
BCDA.US Biocardia Inc
- Market cap
- USD 12.6M
- P/E
- -
- P/B
- 15.07x
- ROE
- -908.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BCDA.US undervalued?
Graham numberThe Graham number of Biocardia Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biocardia Inc fundamental analysis
No fundamental analysis for Biocardia Inc yet.
Biocardia Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an alloge…
Full company profileBiocardia Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Biocardia Inc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 576K | 479K | 625K | 710K | 145K | 1.02M | 1.35M | 477K | 58.0K | 0.00 | - |
| Gross Profit | -170K | -211K | 108K | 352K | 141K | 375K | -10.5M | -7.25M | -4.33M | -505K | - |
| Operating Income | -7.61M | -12.4M | -14.1M | -14.2M | -15.5M | -12.6M | -11.9M | -11.6M | -8.00M | -8.28M | -7.63M |
| EBITDA | -8.54M | -12.2M | -13.9M | -14.5M | -14.9M | -12.6M | -11.8M | -11.5M | -7.88M | -7.72M | -7.41M |
| Net Income | -10.3M | -12.3M | -14.0M | -14.7M | -15.0M | -12.6M | -11.9M | -11.6M | -7.95M | -8.23M | -7.59M |
| EPS | -166 | -2.90 | -49 | -39 | -22 | -11 | -10 | -8.19 | -2.90 | -1.23 | -0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 22.1M | 13.5M | 6.42M | 7.68M | 23.4M | 15.7M | 9.79M | 2.99M | 3.72M | 3.41M | 3.07M |
| Total Liabilities | 1.50M | 2.41M | 2.63M | 5.31M | 4.25M | 5.34M | 4.90M | 4.59M | 2.89M | 2.52M | 2.24M |
| Shareholders' Equity | 20.6M | 11.1M | 3.79M | 2.37M | 19.2M | 10.4M | 4.89M | -1.60M | 837K | 895K | 835K |
| Cash & Short-term Investments | 21.4M | 12.7M | 5.36M | 5.59M | 21.4M | 12.9M | 7.36M | 1.10M | 2.37M | 2.50M | 2.22M |
| Total Debt | - | - | - | 1.14M | 614K | 1.87M | 1.63M | 1.32M | 951K | 528K | 565K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.52M | -8.67M | -11.1M | -9.45M | -12.4M | -10.4M | -10.6M | -9.97M | -8.03M | -7.44M | -6.82M |
| Capital Expenditure | 136K | 136K | 66.0K | 146K | 32.0K | 116K | 70.0K | 12.0K | 6.00K | 7.00K | 5.33K |
| Free Cash Flow | -5.52M | -8.81M | -11.1M | -9.59M | -12.4M | -10.5M | -10.6M | -9.99M | -8.03M | -7.44M | -6.82M |
| Ratios | |||||||||||
| ROE | -50.1% | -110.6% | -368.9% | -620.6% | -78.2% | -121.6% | -243.5% | - | -949.3% | -919.3% | -908.4% |
| ROA | -46.7% | -90.9% | -218.0% | -191.6% | -64.1% | -80.3% | -121.6% | -387.4% | -213.4% | -241.1% | -247.0% |
| Net Profit Margin | -1,789.9% | -2,569.5% | -2,237.9% | -2,071.7% | -10,347.6% | -1,243.4% | -881.1% | -2,425.8% | -13,700.0% | - | - |
| Debt to Equity | - | - | - | 0.48x | 0.03x | 0.18x | 0.33x | - | 1.14x | 0.59x | 0.68x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biocardia Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 346K | 0.51 | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:15 on May 30, 2024.
Who owns Biocardia Inc
- Insiders 18.82%
- Institutions 14.40%
- Public & others 66.78%
- Shares outstanding 15.1M
- Free float 12.3M
Top funds holding BCDA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Abante Quant Value FI | 72.5K | 0.48% | +86.60% | Aug 2026 |
| Fidelity Extended Market Index | 58.1K | 0.38% | -0.38% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 55.6K | 0.37% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 10.5K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 3.24K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding BCDA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citigroup Inc | 398K | 2.63% | 0.00% | Jun 2026 |
| CM Management, LLC | 300K | 1.98% | +130.77% | Jun 2026 |
| Vanguard Capital Management, LLC | 125K | 0.82% | 0.00% | Jun 2026 |
| Pingora Partners LLC | 120K | 0.80% | +236.84% | Jun 2026 |
| UBS Group AG | 77.6K | 0.51% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 66.7K | 0.44% | -29.30% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 66.3K | 0.44% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 38.8K | 0.26% | -0.05% | Jun 2026 |
| Brown Advisory Holdings Inc | 35.5K | 0.23% | 0.00% | Jun 2026 |
| Commonwealth Equity Services, LLC | 23.4K | 0.15% | +27.89% | Jun 2026 |
| Citadel Advisors Llc | 23.0K | 0.15% | -63.78% | Jun 2026 |
| StoneX Group Inc | 20.0K | 0.13% | 0.00% | Jun 2026 |
| Wealth Enhancement Advisory Services, LLC | 18.5K | 0.12% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 12.9K | 0.09% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 3.19K | 0.02% | +7.02% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 3.11K | 0.02% | 0.00% | Jun 2026 |
| Allied Private Wealth LLC | 1.45K | 0.01% | 0.00% | Jun 2026 |
| Global Retirement Partners, LLC. | 411.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 9.00 | 0.00% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 1.00 | 0.00% | 0.00% | Jun 2026 |
Biocardia Inc company profile
- Company name
- Biocardia Inc
- Ticker
- BCDA.US
- Exchange
- USA Stocks
- Listed since
- Mar 14, 2008
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 320 Soquel Way, Sunnyvale, CA, United States, 94085
- Phone
- 650 226 0120
- Website
- biocardia.com
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.
Biocardia Inc management
4- Dr. Peter A. Altman Ph.D.CEO, President & Director · born 1967
- Mr. David McClungChief Financial Officer · born 1963
- Mr. Edward M. GillisSenior Vice President of Devices · born 1962
- Ms. Miranda Peto BenvenutiInvestor Relations Executive